Recognition
of a pattern of microbial RNA by toll-like receptor (TLR) 3 and
cytoplasmic RNA sensors promotes activation of innate immunity in
dendritic cells,2) induces cytokine3) production,
and activation of cellular immunity. Conventionally, double-stranded
virus RNA (such as polyI:C) have shown strong anti-cancer effect, and
have been considered as promising as vaccine adjuvants. However,
clinical application has been abandoned due to side effects such as
severe inflammation and cytokinemia. At this time, we have developed a
TLR3-specific ligand4) with a specified
structure and function by a chemical biology method, which has been
shown to induce NK/CTL dependent anti-cancer activation in a mouse
transplanted cancer model. Since this new TLR3 ligand does not activate
cytoplasmic RNA sensors (molecules which detect virus RNA), nor does it
induce excess inflammatory cytokine production, application in an
anticancer vaccine as a non-inflammatory nucleic acid immunological
adjuvant with fewer side effects. 1) Adjuvant: A substance which can increase the body’s immune function, also called as antigenic strengthening agent. 2) Dendritic cells: Cells which play a central role in the immune system. These cells have strong antigen-presenting capacity to activate helper-T cells, which can detect the existence of cancer cells. 3) Cytokines: Proteins released from cells which can transmit information between cells. 4) Ligand: A substance which specifically binds and activates a specific receptor cell. In this case, it applies to an RNA derivative which binds and activates TLR3. |
||
Only good, independent and reliable information about health from experts.
Tuesday, March 3, 2015
Development of a Non-Inflammatory Anti-tumor Vaccine Adjuvant: Expecting no cytokine toxicity with application to immunotherapy
Hokkaido University (Japan) succeeded in the chemical synthesis and development of a functionally-defined cancer-suppressing nucleic acid adjuvant1) which does not induce excessive inflammatory cytokines. This new nucleic acid adjuvant activates only toll-like receptor 3
(TLR3), and does not activate other functional molecules (such as
RNA/DNA sensors). This adjuvant has fewer side effects, and is expected to contribute
to the development of anti-tumor immune vaccines in the treatment of
cancer, bringing good prognosis to many patients.